Oscar Health, Inc. (OSCR) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 254.21%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 254.21% | Share-based compensation / revenue. Period ending 2026-06-30. $75.19M ÷ $29.58M × 100 ≈ 254.21% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 29.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 75.19M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 629.72M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $29.58M | $75.19M | $629.72M | (m) | (m) | 254.21% | (m) | (m) |
| 2026-03-31 | (m) | $29.98M | $78.65M | $10.61M | (m) | (m) | 262.33% | (m) | (m) |
| 2025-12-31 | (m) | $28.59M | $87.65M | $-396.36M | (m) | (m) | 306.56% | (m) | (m) |
| 2025-09-30 | (m) | $24.44M | $95.42M | $-210.34M | (m) | (m) | 390.44% | (m) | (m) |
| 2025-06-30 | (m) | $20.54M | $104.25M | $-129.47M | (m) | (m) | 507.60% | (m) | (m) |
| 2025-03-31 | (m) | $19.27M | $108.85M | $168.83M | (m) | (m) | 564.83% | (m) | (m) |
| 2024-12-31 | (m) | $20.58M | $109.82M | $57.27M | (m) | (m) | 533.75% | (m) | (m) |
| 2024-09-30 | (m) | $15.58M | $110.11M | $59.52M | (m) | (m) | 706.88% | (m) | (m) |
| 2024-06-30 | (m) | $16.22M | $109.57M | $49.65M | (m) | (m) | 675.55% | (m) | (m) |
| 2024-03-31 | (m) | $16.07M | $114.13M | $-24.69M | $24.37M | (m) | 710.10% | -1.01× | Reported |
| 2023-12-31 | (m) | $15.44M | $159.68M | $-235.62M | $24.60M | (m) | 1034.08% | -9.58× | Reported |
| 2023-09-30 | (m) | $14.29M | $162.63M | $-312.62M | $24.52M | (m) | 1137.82% | -12.75× | Reported |
| 2023-06-30 | (m) | $29.84M | $162.42M | $-446.75M | $24.52M | (m) | 544.25% | -18.22× | Reported |
| 2023-03-31 | (m) | $46.44M | $156.13M | $-546.70M | $24.54M | (m) | 336.21% | -22.28× | Reported |
| 2022-12-31 | (m) | $61.05M | $112.33M | $-589.87M | $22.62M | (m) | 184.00% | -26.07× | Reported |
| 2022-09-30 | (m) | $1.89B | $111.51M | $-563.64M | $16.89M | (m) | 5.88% | -33.38× | Reported |
| 2022-06-30 | (m) | $1.88B | $103.59M | $-582.95M | $11.16M | (m) | 5.52% | -52.25× | Reported |
| 2022-03-31 | (m) | $1.86B | $94.87M | $-548.97M | $5.24M | (m) | 5.11% | -104.69× | Reported |
| 2021-12-31 | (m) | $1.84B | $86.30M | $-544.48M | $4.72M | (m) | 4.69% | -115.36× | Reported |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $462.80M | $35.87M | $-402.27M | $3.51M | (m) | 7.75% | -114.48× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $488.19M | $33.56M | $-259.39M | $0.00 | (m) | 6.87% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.